Weijia Fang, Md
Clinical trials sponsored by Weijia Fang, Md, explained in plain language.
-
New cell therapy targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called PTC13 (a type of CAR-T) for people with advanced solid tumors that have not responded to standard treatments. The therapy targets a protein called CEA found on many cancer cells, including colorectal, stomach, and pancreatic …
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Engineered immune cells take on Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new treatment called Anti-CEA CAR-T for people with advanced solid tumors (like colorectal or stomach cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target a protein called CEA on …
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC